Centrum Medyczne Medyk Sp. z o.o.

The site focuses on Neoplasms, specifically on hormone receptor‑positive and HER2‑negative locally advanced, unresectable or metastatic breast cancer. Current studies aim to test innovative combination regimens that pair an AKT pathway inhibitor with CDK4/6 inhibitors and endocrine therapy to improve patient outcomes.

• Combination therapy targeting AKT and cell‑cycle pathways
• Biomarker‑guided enrollment based on PIK3CA, AKT1, PTEN status
• Assessment of progression‑free survival as primary efficacy endpoint

With a team of 13 investigators, Centrum Medyczne Medyk in Rzeszow is contributing valuable data to advance treatment options for this breast cancer subtype.

In the area of Digestive System Diseases, the centre conducts trials on ulcerative colitis, evaluating new therapeutic agents designed to induce remission in patients with moderate to severe disease activity. The research seeks to enhance disease control while monitoring safety and patient‑reported outcomes.

• Evaluation of clinical response and remission rates
• Safety monitoring in an active disease population
• Impact on quality of life and daily functioning

The ongoing work at Centrum Medyczne Medyk reflects a commitment to improving care for individuals living with inflammatory bowel conditions.